Delayed cancer diagnosis claims are among the most frequently screened and most frequently declined files in a medical malpractice practice. The negligence is often easy to see: a palpable breast mass attributed to a cyst without imaging, rectal bleeding written off as hemorrhoids in a 48-year-old, a lung nodule flagged by radiology and never followed. The hard part is causation. When the patient's prognosis was guarded even at the earlier date, the defense argues the delay changed nothing. Whether that argument wins depends heavily on which state's law applies and how well the plaintiff's experts reconstruct the tumor's history.
The traditional rule and why it fails these patients
Under the traditional all-or-nothing approach, the plaintiff must prove that it is more likely than not that the negligence caused the injury. In a delayed diagnosis case, that means showing a better than even chance of survival or cure at the time of the missed diagnosis. A patient whose five-year survival was 40 percent at the earlier stage and 10 percent at diagnosis has lost three quarters of their chance, yet under the traditional rule recovers nothing, because the starting odds never crossed 50 percent.
California follows the traditional rule. Its courts have declined to adopt loss of chance as an independent theory, so a California plaintiff must still prove that earlier diagnosis would more probably than not have produced a better outcome. That makes expert framing critical, as discussed below.
The loss-of-chance alternative
A substantial group of states have adopted some form of the loss-of-chance doctrine. The Washington Supreme Court's 1983 decision in Herskovits v. Group Health Cooperative is the usual starting point; the Massachusetts Supreme Judicial Court's 2008 decision in Matsuyama v. Birnbaum is the most detailed modern treatment and involved a missed gastric cancer. The approaches fall into roughly three groups:
- Relaxed causation. Some states let the case go to the jury on a showing that the negligence increased the risk of harm, then allow full damages if the jury finds causation.
- Proportional damages. The more common modern approach treats the lost chance itself as the injury. Damages equal the full value of the death or injury multiplied by the percentage of chance lost. A 30-point reduction in survival yields 30 percent of full wrongful death damages.
- Outright rejection. Other states, by statute or decision, reject the doctrine and hold to the preponderance rule.
Before accepting the file, confirm which bucket the forum falls into and whether the doctrine extends to cases where the patient is still alive. Several states recognize loss of chance only in death cases, which leaves living patients with a reduced prognosis in a gap.
Reconstructing the tumor's timeline
Regardless of doctrine, the core expert work is the same: establish what the cancer looked like on the date it should have been found. That requires a disciplined retrospective staging opinion.
Back-calculating stage
Oncology experts estimate earlier stage using tumor doubling time, the size and nodal status at actual diagnosis, and any intervening imaging. A lung nodule measured at 8 mm on a scan that went unread and 34 mm with mediastinal nodes 14 months later supports a credible opinion that the cancer was stage I at the earlier date. Defense experts will attack the doubling-time assumptions, so the plaintiff's expert should cite the range for that histology and show the opinion holds at the conservative end.
Matching stage to survival data
Once earlier stage is established, survival figures come from published stage-specific data such as SEER statistics and the AJCC staging literature. Use the data set that matches the histology, grade, and molecular markers as closely as possible. A generic all-comers figure invites cross-examination about why the patient's specific subtype was ignored.
Treatment differences
Survival is only part of the harm. Earlier diagnosis may have meant lumpectomy instead of mastectomy, surgery without chemotherapy, or a resection rather than palliative care. Those treatment differences are compensable even when long-term survival odds are disputed, and in a traditional-rule state they can carry the case on their own. Have the treating or retained oncologist describe the treatment path the patient would likely have had, step by step.
The standard of care side
Delayed diagnosis claims usually involve one of a few failure patterns, each with its own expert profile:
- Failure to order indicated screening or diagnostic workup, which calls for a primary care or specialty expert in the defendant's field.
- Radiology or pathology misread, which requires a peer reviewer who can testify the finding was visible and reportable.
- Failure to communicate or follow up an abnormal result, which often implicates systems failures and may reach the health system as well as the physician.
Match each defendant with a same-specialty expert and keep the causation opinions with oncology. Standard-of-care experts who stray into survival percentages are an easy target on cross.
Damages modeling under proportional rules
In a proportional-damages state, the damages presentation has two parts: the full value of the harm and the percentage lost. Plaintiffs sometimes underinvest in the first because the multiplier seems to shrink everything. That is a mistake. A 35 percent share of a well-supported full-value figure, including life care, lost earnings, and non-economic damages, can still produce a meaningful verdict. Damages caps complicate the math; in states with noneconomic caps, determine whether the cap applies before or after the proportional reduction, because the answer can change the recoverable figure significantly.
Related coverage on causation fights and expert sourcing appears in our medical malpractice section, and wrongful death valuation issues are covered under wrongful death.
Screening these files efficiently
Given the expert cost, an early oncology review before suit is worth the investment. The screening questions are straightforward: what was the stage at actual diagnosis, what was the length of the delay, what does doubling-time analysis suggest about earlier stage, and what was the survival and treatment difference between the two stages. If the delay was short relative to the tumor's growth rate, or the cancer was already metastatic at the earlier date, the case is weak under any doctrine. If the delay spans a stage boundary for a cancer with sharply stage-dependent survival, the case deserves a full workup even where the starting odds were below even.
